About
This site hosts an educational glaucoma staging and interventional pathway tool aligned with an interventional-first philosophy. It is not a clinical decision-making system and does not replace clinician judgment.
What this tool is
Micheletti Interventional Glaucoma Protocol Tool is an evidence-based decision tree designed to help organize glaucoma care into a stage-matched pathway. It first establishes a working diagnosis using simplified inputs (disc appearance, structural thinning, functional loss, and evidence of progression), then suggests next steps aligned with the Interventional Glaucoma (IG) Protocol as the core framework.
Recommendations are further supported by additional leveled evidence and pivotal studies across SLT, procedural pharmaceuticals, and MIGS.
What this tool is not
This tool is intended for educational and informational purposes only and should not be used as a basis for clinical decision-making. It does not replace professional medical advice, diagnosis, or treatment.
Clinical Advisory Group
To ensure the IG Protocol tool reflects a broad range of real-world interventional glaucoma practice patterns, MM Eye Media, LLC is assembling a small Clinical Advisory Group of surgeons to review evidence, identify edge cases, and provide feedback on usability and clinical logic.
Details will be released soon.
About the creator: J. Morgan Micheletti, MD, FACS
J. Morgan Micheletti, MD, FACS, is a board-certified ophthalmologist, partner, Director of Research, and Fellowship Director at Berkeley Eye Center. He has performed over 10,000 surgeries, specializing in cataract, vision-correction, microinvasive glaucoma, and complex anterior segment surgery. Dr. Micheletti serves as a medical advisor to over 20 companies, is the Director of Clinical Strategy for Synopic, and is on the board of directors for the Society of Excellence in Eyecare (SEE). He is also a Fellow of the World College of Refractive Surgery and Visual Sciences.
Accolades and recognition
Dr. Micheletti has received numerous accolades, with the Outstanding Young Texas Ex Award being one of his most prestigious honors. Awarded in September 2024, this recognition is presented by The University of Texas and The Texas Exes to alumni under 40 who have demonstrated significant professional achievements and contributions to their field.
- Named to the 40-under-40 list of ophthalmologists in the United States.
- Received the Intraocular Implant and Refractive Society of India (IIRSI) gold medal in July 2024 in Chennai, India.
- Recognized as one of the Best Cataract Surgeons in America.
- Castle Connolly Top Doctor.
- Awarded Incredible Innovation and Scientific Contribution by RW Ophthalmology.
Innovation, research, and clinical trials
A serial inventor with six patent-pending surgical devices, including a sustainable surgical blade, electronic lens implant, and glaucoma implant, Dr. Micheletti pioneered two surgical techniques and created an AI-driven nomogram for ICL sizing. Recognized as an expert in advanced technology IOLs, he has contributed hundreds of publications and lectures and served as an investigator in over 15 clinical trials.
As part of his research efforts, he launched surgical devices to the International Space Station in late 2024 aboard a Falcon 9 rocket. You can explore selected peer-reviewed publications on the Supporting Evidence page.
Academic and professional background
He attended The University of Texas at Austin, where he graduated with a Bachelor of Science in Cellular and Molecular Biology with High Honors and Special Honors in Biology. He earned multiple endowed presidential scholarships, was a University of Texas Distinguished College Scholar, and was selected as an inaugural member of the Freshman Research Initiative, which led to multiple scientific publications in RNA aptamers and DNA pools.
Dr. Micheletti received his medical degree from Baylor College of Medicine in Houston, where he served as president of the BCM Ophthalmology Interest Group and as an elected class officer and representative on the Medical Student Council. He completed a transitional internship at Emory University School of Medicine and then residency training in ophthalmology at the Emory Eye Center. While at Emory, he published multiple peer-reviewed articles and served as an Advocacy Ambassador with the American Academy of Ophthalmology, working with local, state, and national leaders to improve eye care nationwide.
Clinical focus
At Berkeley Eye Center, Dr. Micheletti’s clinical interests include advanced cataract surgery, surgical correction of presbyopia, cutting-edge refractive surgery, minimally invasive glaucoma surgery, complex IOL management, and complex anterior segment surgery. As the Director of Research and Fellowship Director, he is an investigator on numerous industry-sponsored FDA clinical trials and investigator-initiated studies.
Professional service
Dr. Micheletti is a diplomate of the American Board of Ophthalmology, a Fellow of the American Academy of Ophthalmology (AAO), and a Fellow of the American College of Surgeons. He chairs the AECOS Research Committee, serves on the AAO ONE Network Cataract Committee and the Young Eye Surgeons Committee for the American Society of Cataract and Refractive Surgery, and is a member of the Health Policy Committee for the Society of Excellence in Eyecare. He is an active member of the American-European Congress of Ophthalmic Surgery (AECOS), the Texas Ophthalmological Association, and the Houston Ophthalmological Society.
Outside of work
Outside of work, he enjoys spending time with his wife and three children, woodworking, snowboarding, and golf.
Usage and IP
Use of this site is subject to the Disclaimer and Agreement shown in the tool. Users agree not to copy, distribute, reverse-engineer, or replicate the software, its components, or the data herein without express permission.